Peer-reviewedCC BY 4.0HemaSphere
The thrombopoietin receptor S264F mutant drives MPN with marrow fibrosis through a dual mechanism
Related
- Treatment patterns and safety outcomes after splenectomy or thrombopoietin receptor agonists as second-line therapy for immune thrombocytopenia: Korean claims-based study.
- Mechanism of growth arrest-specific protein 6/Axl receptor tyrosine kinase signaling pathway in promoting macrophage polarization and contributing to interstitial fibrosis in IgA nephropathy
- Molecular Mechanisms and Therapeutic Advances in KRAS G12C‐Mutant Non‐Small Cell Lung Cancer: Toward Mechanism‐Guided Longitudinal Management
- Targeting mutant NPM1-expressing AML with T cell receptor-like antibodies
- Tamoxifen and Doxorubicin Synergistically Target Estrogen Receptor beta-Mutant p53-p73 Axis, a Therapeutically Actionable Vulnerability in Triple Negative Breast Cancer
BibTeX
@article{lees2026thrombopoietin,
title = {{The thrombopoietin receptor S264F mutant drives MPN with marrow fibrosis through a dual mechanism}},
author = {Charlotte Lees and Emile Brandt and Emmanuel Dutranoix and Gabriel Levy and Bogdan I. Iorga and Hosuk Ryou and Jens Rittscher and Daniel Royston and Stefan Constantinescu and Adam Mead},
journal = {HemaSphere},
year = {2026},
month = oct,
doi = {10.1002/hem3.70437},
url = {https://hal.science/hal-05790492v1},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - The thrombopoietin receptor S264F mutant drives MPN with marrow fibrosis through a dual mechanism
AU - Charlotte Lees
AU - Emile Brandt
AU - Emmanuel Dutranoix
AU - Gabriel Levy
AU - Bogdan I. Iorga
AU - Hosuk Ryou
AU - Jens Rittscher
AU - Daniel Royston
AU - Stefan Constantinescu
AU - Adam Mead
PY - 2026
DA - 2026/10/07
JO - HemaSphere
DO - 10.1002/hem3.70437
UR - https://hal.science/hal-05790492v1
SN - 2572-9241
ER -